Cargando…

Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma

OBJECTIVE: Only few studies have focused on tumor markers used in the preoperative diagnosis of endometriosis-related ovarian neoplasms, and previous studies have only assessed serum CA125 levels. This study investigated the significance of preoperative tumor markers and clinical characteristics in...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinmura, Hiroki, Yoneyama, Koichi, Harigane, Eika, Tsunoda, Yohei, Fukami, Takehiko, Matsushima, Takashi, Takeshita, Toshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362875/
https://www.ncbi.nlm.nih.gov/pubmed/32354795
http://dx.doi.org/10.1136/ijgc-2020-001210
_version_ 1783559577432752128
author Shinmura, Hiroki
Yoneyama, Koichi
Harigane, Eika
Tsunoda, Yohei
Fukami, Takehiko
Matsushima, Takashi
Takeshita, Toshiyuki
author_facet Shinmura, Hiroki
Yoneyama, Koichi
Harigane, Eika
Tsunoda, Yohei
Fukami, Takehiko
Matsushima, Takashi
Takeshita, Toshiyuki
author_sort Shinmura, Hiroki
collection PubMed
description OBJECTIVE: Only few studies have focused on tumor markers used in the preoperative diagnosis of endometriosis-related ovarian neoplasms, and previous studies have only assessed serum CA125 levels. This study investigated the significance of preoperative tumor markers and clinical characteristics in distinguishing endometriosis-related ovarian neoplasms from ovarian endometrioma. METHODS: A case-control study was conducted on 283 women who were diagnosed with confirmed pathology with endometriosis-related ovarian neoplasms (n=21) and ovarian endometrioma (n=262) at a single institution from April 2008 to April 2018. The serum CA125, CA19–9, carcinoembryogenic antigen (CEA), sialyl Lewis-x antigen (SLX), and lactate dehydrogenase (LDH) levels, age, tumor size, and the presence of mural nodule of the patients were analyzed. RESULTS: Patients with endometriosis-related ovarian neoplasms were more likely to be older (48 (range, 26–81) vs 39 (range, 22–68) years, P<0.001), have higher levels of CA19–9 (42 vs 19 U/mL, P=0.013), CEA (1.3 vs 0.84 ng/mL, P=0.007), SLX (41 vs 33 U/mL, P=0.050), and LDH (189 vs 166 U/mL, P<0.001) and larger tumor size (79 vs 55 mm, P=0.001), and present with mural nodule (85.7 vs 4.5 %, P<0.001) than those with ovarian endometrioma. The CA125 levels did not significantly differ between the two groups. The area under the curve for each factor was as follows: CA19-9 level, 0.672 (95% CI 0.52 to 0.83; P=0.013); CEA level, 0.725 (95% CI 0.58 to 0.87; P=0.007); SLX level, 0.670 (95% CI 0.53 to 0.84; P=0.050); LDH level, 0.800 (95% CI 0.70 to 0.90; P<0.001); age, 0.775 (95% CI 0.65 to 0.90; P<0.001); and tumor size, 0.709 (95% CI 0.56 to 0.86; P=0.001). Age was a better marker than CA19-9, CEA, and SLX levels according to the receiver operating characteristic curve analysis. The optimal cut-off values for age and tumor size were 47 years and 80 mm, respectively. CONCLUSIONS: The assessment of serum CA19–9, CEA, SLX, and LDH levels may be a useful tool in the preoperative evaluation to differentiate between endometriosis-related ovarian neoplasms and ovarian endometrioma.
format Online
Article
Text
id pubmed-7362875
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-73628752020-07-16 Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma Shinmura, Hiroki Yoneyama, Koichi Harigane, Eika Tsunoda, Yohei Fukami, Takehiko Matsushima, Takashi Takeshita, Toshiyuki Int J Gynecol Cancer Original Research OBJECTIVE: Only few studies have focused on tumor markers used in the preoperative diagnosis of endometriosis-related ovarian neoplasms, and previous studies have only assessed serum CA125 levels. This study investigated the significance of preoperative tumor markers and clinical characteristics in distinguishing endometriosis-related ovarian neoplasms from ovarian endometrioma. METHODS: A case-control study was conducted on 283 women who were diagnosed with confirmed pathology with endometriosis-related ovarian neoplasms (n=21) and ovarian endometrioma (n=262) at a single institution from April 2008 to April 2018. The serum CA125, CA19–9, carcinoembryogenic antigen (CEA), sialyl Lewis-x antigen (SLX), and lactate dehydrogenase (LDH) levels, age, tumor size, and the presence of mural nodule of the patients were analyzed. RESULTS: Patients with endometriosis-related ovarian neoplasms were more likely to be older (48 (range, 26–81) vs 39 (range, 22–68) years, P<0.001), have higher levels of CA19–9 (42 vs 19 U/mL, P=0.013), CEA (1.3 vs 0.84 ng/mL, P=0.007), SLX (41 vs 33 U/mL, P=0.050), and LDH (189 vs 166 U/mL, P<0.001) and larger tumor size (79 vs 55 mm, P=0.001), and present with mural nodule (85.7 vs 4.5 %, P<0.001) than those with ovarian endometrioma. The CA125 levels did not significantly differ between the two groups. The area under the curve for each factor was as follows: CA19-9 level, 0.672 (95% CI 0.52 to 0.83; P=0.013); CEA level, 0.725 (95% CI 0.58 to 0.87; P=0.007); SLX level, 0.670 (95% CI 0.53 to 0.84; P=0.050); LDH level, 0.800 (95% CI 0.70 to 0.90; P<0.001); age, 0.775 (95% CI 0.65 to 0.90; P<0.001); and tumor size, 0.709 (95% CI 0.56 to 0.86; P=0.001). Age was a better marker than CA19-9, CEA, and SLX levels according to the receiver operating characteristic curve analysis. The optimal cut-off values for age and tumor size were 47 years and 80 mm, respectively. CONCLUSIONS: The assessment of serum CA19–9, CEA, SLX, and LDH levels may be a useful tool in the preoperative evaluation to differentiate between endometriosis-related ovarian neoplasms and ovarian endometrioma. BMJ Publishing Group 2020-06 2020-04-30 /pmc/articles/PMC7362875/ /pubmed/32354795 http://dx.doi.org/10.1136/ijgc-2020-001210 Text en © IGCS and ESGO 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research
Shinmura, Hiroki
Yoneyama, Koichi
Harigane, Eika
Tsunoda, Yohei
Fukami, Takehiko
Matsushima, Takashi
Takeshita, Toshiyuki
Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma
title Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma
title_full Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma
title_fullStr Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma
title_full_unstemmed Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma
title_short Use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma
title_sort use of tumor markers to distinguish endometriosis-related ovarian neoplasms from ovarian endometrioma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7362875/
https://www.ncbi.nlm.nih.gov/pubmed/32354795
http://dx.doi.org/10.1136/ijgc-2020-001210
work_keys_str_mv AT shinmurahiroki useoftumormarkerstodistinguishendometriosisrelatedovarianneoplasmsfromovarianendometrioma
AT yoneyamakoichi useoftumormarkerstodistinguishendometriosisrelatedovarianneoplasmsfromovarianendometrioma
AT hariganeeika useoftumormarkerstodistinguishendometriosisrelatedovarianneoplasmsfromovarianendometrioma
AT tsunodayohei useoftumormarkerstodistinguishendometriosisrelatedovarianneoplasmsfromovarianendometrioma
AT fukamitakehiko useoftumormarkerstodistinguishendometriosisrelatedovarianneoplasmsfromovarianendometrioma
AT matsushimatakashi useoftumormarkerstodistinguishendometriosisrelatedovarianneoplasmsfromovarianendometrioma
AT takeshitatoshiyuki useoftumormarkerstodistinguishendometriosisrelatedovarianneoplasmsfromovarianendometrioma